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Carcinoma of the pancreas is the fourth leading
cause of cancer death in the western world and has
an overall 5-year survival of one per cent
(Malagelada, 1979). During the past four decades
the incidence trebled in the United States and
doubled in England and Wales (Krain, 1970;
Morgan & Wirmsley, 1977). One cause for the poor
prognosis is the late diagnosis of the disease; the
pancreas is deeply seated in the abdominal cavity
and the initial symptoms associated with neoplastic
change are generally vague and non-specific.
Moreover, there are few aetiological leads to
indicate precautionary measures that might clearly
be taken against developing pancreatic cancer
(Cordis & Gold, 1984). Thus early detection at the
stage of potentially curative resection could provide
the greatest impact in the management of this lethal
disease.
Despite an extensive search, no single tumour
marker that is currently available can reliably
distinguish patients with pancreatic carcinoma from
those with pancreatitis on other alimentary cancers
(Williamson, 1985). The oncofoetal antigen CA-50
has been reported in the serum of most carcinoma
patients (Holmgren et al., 1984). The present report
suggests that serum CA-50 levels may provide a
useful discrimination between inflammatory and
neoplastic disease of the pancreas.
Serum samples were collected from 50 normal
subjects, 9 patients with pancreatitis (5 acute, 4
chronic) and 26 patients with carcinoma of the
pancreas. The mean age for the normal,
pancreatitis and cancer groups were 50, 44 and 58
years, and the male:female ratios were 13:12, 7:2
and 13:13, respectively.
Serum samples were obtained 1 or 2 days before
operation from patients that underwent surgery or
at a routine clinic visit from inoperable patients and
those with benign disease. Samples were stored at
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-70°C until used. A radioimmunoassay (RIA) for
the detection of the human carcinoma-associated
antigen CA-50 in serum using a commercial kit
Can Ag CA-50 radioimmunoassay (Stena
Diagnostics, Sweden) was used. The Can Ag CA-50
RIA inhibition test is based on the ability of serum
containing the CA-50 antigen to inhibit the binding
of C-50 monoclonal antibody (IgM) to plastic
adsorbed purified CA-50 ganglioside antigen
(Holmgren et al., 1984). An antimouse immuno-
globulin preparation labelled with radioiodine was
used to detect the bound uninhibited C-50
antibody.
The test serum (100ul) was mixed with 100Ml
C-50 monoclonal antibody (- 1 mg I1-I in foetal
calf serum added with 0.1% Tween) in a test tube
and the mixture gently agitated for 90min at room
temperature. A polystyrene bead coated with CA-
50 ganglioside antigen was then added and
incubation continued for a further 4h at room
temperature. The liquid was then removed by
aspiration and the bead washed three times in 2ml
PBS. A total of 200Ml 1251 labelled antimouse IgM
(Kirkegaard Inc., Maryland, USA) or antimouse
total immunoi 'obulin antibody (Amersham
International, B3iickinghi mnshire) diluted in PBS
supplemented with bovine serum albumin 10gl-
was then added to the tube and incubated with the
antigen coated bead overnight at 4°C. This was
followed by removal of the liquid, repeated washing
in PBS, and determination in a gamma scintillation
counter of the specifically bound radioactivity in
each tube resulting from binding of the second
labelled antibody to the beads. Results obtained
with the test serum specimens were expressed as
percentage inhibition in relation to a negative
standard (foetal calf serum) using the formula: 100-
(c.p.m. in test specimen tube c.p.m. in negative
standard tube x 100) =percentage inhibition. Each
test was performed in duplicate; the results
presented are the means. In some instances
titrations of specimens were performed by testing
twofold serial dilutions.
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The C-S0 monoclonal antibody used was
prepared from tissue culture medium in which the
C-50 hydridoma cell line (Lindholm et al., 1983)
had been grown for several days to a high cell
density. The CA-50 ganglioside antigen preparation
used was isolated from a human pancreatic
adenocarcinoma as described (Nilsson et al., 1984).
The serum CA-50 levels were expressed as Uml-P
following their transfer from CPM. The level of
17Uml-1 was used as a cut-off level between
benign and malignant liver diseases.
All 50 normal subjects and 8 of the 9 patients
with pancreatitis had CA-50 level below 17Uml-1
(Figure 1). The only exception was a severely ill
man with acute pancreatitis, who was sampled
during his stay in the intensive care unit and had a
CA-50 level of 25Uml-1.
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Figure 1 CA-50 levels in control subjects and patients
with pathological pancreatic conditions.
In the cancer group, 24/26 (92%) patients with
pancreatic carcinomas had serum concentrations
>17Uml-1 (i.e.: positive). One patient remained
negative 2 years after an apparently curative
resection with no evidence of recurrence.
The overall mean of CA-50 concentration in
cancer patients with serum levels >17Uml- was
65+46 (range 20-118).
The overall sensitivity of the CA-50 test in
pancreatic carcinoma was thus 91% (24 of 26). The
false positive rate was nil in normal subjects and
11% (1 of 9) in the group of patients with
pancreatitis. These results compare favourably with
carcinoembryonic antigen (CEA) in the screening of
pancreatic cancer. Recent series (Zamcheck, 1976)
have shown CEA sensitivity to be - 34%. CEA has
also been reported to be elevated in 18-43% of
patients with pancreatitis (Patterson & Alpert,
1983). Recently CA 19-9 was described in
histological sections of patients with pancreatic
carcinomas (Haglund et al., 1986a). The CA 19-9
stained positively in 87% of well to moderately
differentiated carcinomas. Serum CA 19-9 levels
were also reported elevated in 78% of patients with
pancreatic cancer (Haglund et al., 1986b). Other
diagnostic modalities (such as computerised axial
tomography, ultrasound scan and angiography) are
either expensive or invasive and are likely to be
unsuitable in routine screening in the high risk
group of patients or those with vague abdominal
symptoms. Therefore the availability of the CA-50
RIA test could be a useful tool for the clinician in
the differential diagnosis of pancreatic disease. It
remains to be seen whether CA-50 is able to detect
carcinoma at an early enough stage for a truely
curative resection to be undertaken.
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